Clinical trials: Pathological Complete Response
Neoadjuvant Chemoradiotherapy, Locally Advanced Rectal Cancer
THeragnostic Utilities for Neoplastic DisEases of the Rectum by MRI Guided Radiotherapy
Neoadjuvant chemoradiation therapy (nCRT) is the standard treatment modality for locally advanced rectal cancer (LARC), and patients achieving complete response (CR) generally have improved local control, metastasis-free…
- Conditions
- Neoadjuvant Chemoradiotherapy, Locally Advanced Rectal Cancer, Pathological Complete Response
- Trial name
- THUNDER2 (NCT04815694)
- Testing
- RT Dose escalation in LARC patients with an Early Regression Index > 13.1 at second week on nCRT
- Where
- Italy
- Volunteers
- 179 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Breast Cancer, Axillary Lymph Node Metastasis
Ultrasound Monitoring of Clipped Lymph Nodes to Predict Axillary Response After Chemotherapy in Breast Cancer
This study aims to evaluate whether longitudinal multimodal ultrasound can accurately predict axillary pathological response in breast cancer patients who receive neoadjuvant chemotherapy.
- Conditions
- Breast Cancer, Axillary Lymph Node Metastasis, Neoadjuvant Chemotherapy, Pathological Complete Response
- Trial name
- NCT07596472
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Rectal Cancers, Pathological Complete Response
Predicting Pathological Complete Response in Rectal Cancer Using Machine Learning
This study aims to develop and validate a robust machine learning-based prediction model utilizing baseline clinical data and magnetic resonance imaging (MRI) features.
- Conditions
- Rectal Cancers, Pathological Complete Response, Neoadjuvant Chemoradiotherapy, Machine Learning
- Trial name
- NCT07509632
- Testing
- No interventions
- Where
- China
- Volunteers
- 320 people
- Sponsor
- Peking University People's Hospital
Breast Cancer, Invasive Breast Carcinoma
Tissue- and Serum-Derived Exosomal microRNAs as Predictors of Neoadjuvant Chemotherapy Response in Breast Cancer
This prospective observational study aims to evaluate whether exosomal microRNA profiles derived from tumor tissue and blood serum are associated with pathological complete response (pCR) to neoadjuvant chemotherapy (NAC) in…
- Conditions
- Breast Cancer, Invasive Breast Carcinoma, Exosomal microRNA, Neoadjuvant Chemotherapy Response
- Trial name
- ExoTSS-BC (NCT07500129)
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Atlas University
Pathological Complete Remission, Objective Response Rate
Adebrelimab Combined With Chemotherapy for the Esophageal Squamous Cell Carcinoma
This study is a prospective, single-arm, phase II exploratory clinical trial. The primary endpoint of this study is to evaluate the pathological complete response (pCR) rate after surgery and to assess the safety of neoadjuvant…
- Conditions
- Pathological Complete Remission, Objective Response Rate, Immune-related Adverse Events, Quality of Life
- Trial name
- NCT07430579
- Testing
- adebrelimab combined with chemotherapy
- Where
- China
- Volunteers
- 25 people
- Sponsor
- The Second Hospital of Shandong University
ESCC, Total Neoadjuvant Treatment
Neoadjuvant Immunochemotherapy and Chemoradiotherapy Followed by Surgery for Advanced Esophageal Squamous Cell Carcinoma
Effective systemic therapy such as nivolumab as an adjuvant therapy has been demonstrated to improve the outcomes of patients receiving neoadjuvant chemoradiotherapy (CRT) for locoregional esophageal cancer.
- Conditions
- ESCC, Total Neoadjuvant Treatment, Pathological Complete Response
- Trial name
- NICE-ESCC (NCT06764355)
- Testing
- Tislelizumab, Paclitaxel, Cisplatin
- Where
- Taiwan
- Volunteers
- 50 people
- Sponsor
- National Taiwan University Hospital
Pathological Complete Response, Rectal Cancer
Clinical Study on the Safety and Relationship of Sintilimab Combined With Chemotherapy in Neoadjuvant Treatment of Locally Advanced Rectal Adenocarcinoma
This study is designed as a single-center, phase II exploratory clinical trial to evaluate the pathological response rate and safety of sintilimab (PD-1 inhibitor) combined with XELOX regimen (oxaliplatin + capecitabine) for…
- Conditions
- Pathological Complete Response, Rectal Cancer, Neoadjuvant Chemoimmunotherapy
- Trial name
- NCT07127497
- Testing
- Sintilimab combined with XELOX
- Where
- China
- Volunteers
- 50 people
- Sponsor
- The First Affiliated Hospital of Anhui Medical University
Esophageal Squamous Cell Carcinoma, Pathological Complete Response
Predicting Pathological Complete Response in Esophageal Squamous Cell Carcinoma Using a Multimodal Model Integrating Clinical, Radiomics, and Deep Learning Features
This multicenter, retrospective cohort study reviews the medical records and CT scans of adults with esophageal squamous cell carcinoma (ESCC) who received neoadjuvant immunotherapy plus chemotherapy before surgery at three…
- Trial name
- pCR-ESCC (NCT07181850)
- Testing
- Standard-of-Care Neoadjuvant Immunochemotherapy (nIT+nCT)
- Where
- China
- Volunteers
- 363 people
- Sponsor
- Nanjing Medical University
Esophageal Squamous Cell Carcinoma, Neoadjuvant Immunochemotherapy
Deep Learning Model Predicts Pathological Complete Response of Esophageal Squamous Cell Carcinoma Following Neoadjuvant Immunochemotherapy
This study aims to develop and validate a deep learning model to predict pathological complete response (pCR) in patients with esophageal squamous cell carcinoma who have undergone neoadjuvant immunochemotherapy.
- Conditions
- Esophageal Squamous Cell Carcinoma, Neoadjuvant Immunochemotherapy, Pathological Complete Response, Deep Learning
- Trial name
- DL-ESCC (NCT07088354)
- Testing
- The high-throughput extraction of large amounts of quantitative image features from medical images
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Tongji Hospital
Axillary Lymph Node Dissection, Pathological Complete Response
Omission of ALND in Breast Cancer Patients With Axillary pCR
This prospective, single-arm, phase II trial studies axillary lymph node dissection (ALND) to see if it can be safely omitted in breast cancer patients with axillary pathological complete response (pCR) after neoadjuvant systemic…
- Conditions
- Axillary Lymph Node Dissection, Pathological Complete Response, Neoadjuvant Systemic Therapy, Breast Cancer
- Trial name
- NCT05939830
- Testing
- Stained region Lymph Node Biopsy (SrLNB), Regional lymph node radiotherapy (RNI) including the axilla
- Where
- China
- Volunteers
- 92 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Pancreatic Cancer, Neoadjuvant Therapy
Long-term Survival Outcomes According to the Pathologic Response After Neoadjuvant Treatment in PDAC and the Fate of the Patients with Good CAP Grade
1. Neoadjuvant treatment (NAT) is increasingly used in managing pancreatic ductal adenocarcinoma (PDAC), necessitating dependable methods to evaluate tumor response. 2.
- Conditions
- Pancreatic Cancer, Neoadjuvant Therapy, Pathological Complete Response
- Trial name
- CAP with NAT (NCT06630481)
- Testing
- neoadjuvant therapy
- Volunteers
- 462 people
- Sponsor
- Seoul National University Hospital
Deep Learning Model, Pathological Complete Response
Deep Learning Model Predicts Pathological Complete Response of Lung Cancer Following Neoadjuvant Immunochemotherapy
This study presents the development and validation of an artificial intelligence (AI) prediction system that utilizes pre-neoadjuvant immunotherapy plain scans and enhanced multimodal CT scans to extract deep learning features.
- Conditions
- Deep Learning Model, Pathological Complete Response, Non-small Cell Lung Cancer, Neoadjuvant Chemoimmunotherapy
- Trial name
- NCT06285058
- Testing
- No interventions
- Volunteers
- 1,000 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Pathological Conditions, Signs and Symptoms
PTC Guiding Neoadjuvant Treatment in Breast Cancer
Patients with breast cancer meet criteria for enrollment are randomized into PTC group or control group. The neoadjuvant therapy regimens are guided by PTC test in the PTC group.
- Trial name
- NCT05103293
- Testing
- patient-derived tumor-like cell clusters drug sensitivity test
- Where
- China
- Volunteers
- 86 people
- Sponsor
- Zhejiang Cancer Hospital
Fasting Mimicking Diet, HER2-negative Breast Cancer
Fasting Mimicking Diet Program to ImpRovE ChemoTherapy in Hormone Receptor Postive (HR+), HER2- Breast Cancer
In preclinical research, short-term fasting (STF) protects tumor-bearing mice against the toxic effects of chemotherapy, improves the CD8+ effector T-cell intratumor infiltration, while enhancing the chemotherapy efficacy.
- Conditions
- Fasting Mimicking Diet, HER2-negative Breast Cancer, Hormone Receptor-positive Breast Cancer, Pathological Complete Response
- Trial name
- DIRECT-2 (NCT05503108)
- Testing
- Fasting Mimicking diet program
- Where
- 7 sites in Netherlands
- Volunteers
- 10 people
- Sponsor
- Leiden University Medical Center
Non-small Cell Lung Cancer, Neoadjuvant Chemoimmunotherapy
Deep Learning Signature for Predicting Complete Pathological Response to Neoadjuvant Chemoimmunotherapy in Non-small Cell Lung Cancer
The purpose of this study is to evaluate the performance of a CT/PET/ WSI-based deep learning signature for predicting complete pathological response to neoadjuvant chemoimmunotherapy in non-small cell lung cancer
- Conditions
- Non-small Cell Lung Cancer, Neoadjuvant Chemoimmunotherapy, Complete Pathological Response
- Trial name
- NCT05925751
- Testing
- CT/PET/WSI-based Deep Learning Signature
- Where
- 3 sites in China
- Volunteers
- 100 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Rectal Cancer, Pathological Complete Response
Effect of Concurrent Capecitabine-based Long-term Radiotherapy Followed by XELOX Plus TME in Patients With High Risk Rectal Cancer: a Multi-centers, Randomized Controlled, Open-Label Trial
The purpose of this study was to evaluate the effect of concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX pre- a delayed TME compared with 6 cycles XELOX post- a Regular Timing TME in patients with…
- Conditions
- Rectal Cancer, Pathological Complete Response, Disease Free Survival
- Trial name
- EXPLORE (NCT03038256)
- Testing
- concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME, concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX
- Where
- 2 sites in China
- Volunteers
- 244 people
- Sponsor
- Peking University People's Hospital
HER2-negative Breast Cancer, Neoadjuvant Therapy
Efficacy and Safety of Combinition of Camrelizumab in Second-line Neoadjuvant Chemotherapy and Adjuvant Therapy
The achievement of pathological complete response (pCR) after neoadjuvant chemotherapy (NACT) is associated with improved outcome across all breast cancer (BC) subtypes.
- Conditions
- HER2-negative Breast Cancer, Neoadjuvant Therapy, Pathological Complete Response, Immunotherapy
- Trial name
- NCT04848454
- Testing
- Camrelizumab with vinorelbine and cisplatin
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking University First Hospital
EUS-FNA, Rectal Cancer
TRUS-FNA For The Prediction Of pCR After Neoadjuvant Treatment In Rectal Cancer
Colorectal cancer is one of the most malignancies worldwide. The dominant clinical research strategy of LARC includes neoadjuvant chemoradiotherapy before radical surgery followed combined with adjuvant treatment.
- Conditions
- EUS-FNA, Rectal Cancer, Pathological Complete Remission
- Trial name
- NCT04939103
- Testing
- TRUS-FNA
- Where
- China
- Volunteers
- 63 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Refusal of Breast Surgery in Patients With Breast Cancer With a cCR After NST and a Confirmed Pathological Complete Response (pCR) Using VAB and SLNB
Refusal of Breast Surgery in Patients With Breast Cancer With a Clinical Complete Response (cCR) After Neoadjuvant Systemic Therapy and a Confirmed Pathological Complete Response (pCR) Using Vacuum-assisted Biopsy (VAB) and Sentinel Lymph Node Biopsy (SLNB)
The main goal of the study is to abandon breast surgery in patients with breast cancer with a clinical complete response (cCR) after neoadjuvant systemic therapy and confirmed pCR using Vacuum-assisted biopsy (VAB) and sentinel…
- Trial name
- VAB (NCT04293796)
- Testing
- Vacuum-assisted biopsy
- Where
- Russia
- Volunteers
- 60 people
- Sponsor
- N.N. Petrov National Medical Research Center of Oncology
Breast Neoplasm, Neoadjuvant Therapy
RISAS Procedure in Node Positive Breast Cancer Following NAC
Chemotherapy in clinically node positive breast cancer patients is increasingly administrated in a neoadjuvant setting. The standard treatment regimen in these cases is then: neoadjuvant chemotherapy (NAC) followed by breast…
- Conditions
- Breast Neoplasm, Neoadjuvant Therapy, Axillary Lymph Nodes, Pathological Complete Response
- Trial name
- RISAS (NCT02800317)
- Testing
- RISAS
- Where
- 14 sites in Netherlands
- Volunteers
- 248 people
- Sponsor
- Erasmus Medical Center